US Broker Ratings

Amylyx Pharmaceuticals, Inc. (AMLX) Investor Outlook: Exploring a Potential 120% Upside in Biotechnology

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a clinical-stage biotech firm based in Cambridge, Massachusetts, offers an intriguing opportunity for investors looking to capitalize on the burgeoning healthcare..

Geron Corporation (GERN) Stock Analysis: Exploring a 149% Potential Upside in Biotech

Geron Corporation (NASDAQ: GERN), a key player in the biotechnology sector, has been capturing investor attention with its promising outlook and significant potential upside. Currently trading..

Oculis Holding AG (OCS) Stock Analysis: A Biotech Gem with 69.9% Potential Upside

For investors seeking promising opportunities in the biotech sector, Oculis Holding AG (OCS) is a name that stands out. The Swiss-based clinical-stage biopharmaceutical company is gaining..

Zevra Therapeutics, Inc. (ZVRA)

⚠️ No article content returned.

..

Bioventus Inc. (BVS) Stock Analysis: Exploring an 88% Potential Upside in the Healthcare Sector

Bioventus Inc. (NASDAQ: BVS) is making waves in the healthcare sector with an enticing potential upside of 88%, as noted by recent analyst ratings. Specializing in..

AMN Healthcare Services Inc (AMN) Stock Analysis: Exploring a Potential 25.82% Upside in the Healthcare Sector

Investors seeking opportunities in the healthcare sector might find AMN Healthcare Services Inc. (NYSE: AMN) an intriguing prospect. Headquartered in Dallas, Texas, AMN provides technology-enabled healthcare..

Claritev Corporation (CTEV) Stock Analysis: Navigating the Complex Terrain of Healthcare Data Analytics

Claritev Corporation (CTEV), a key player in the healthcare sector specializing in health information services, is making waves with its innovative approach to data analytics and..

Valneva SE (VALN) Stock Analysis: Uncovering a 108.85% Potential Upside in the Biotech Arena

Valneva SE (NASDAQ: VALN), a French biotechnology company, is making significant strides in the healthcare sector with its focus on developing vaccines for infectious diseases that..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Biotechnology Innovator with 225.87% Upside Potential

Tyra Biosciences, Inc. (NASDAQ: TYRA) is capturing investor attention with its promising biotechnological innovations and a staggering potential upside of 225.87%. As a clinical-stage biotechnology company,..

Replimune Group, Inc. (REPL)

⚠️ No article content returned.

..

Capricor Therapeutics, Inc. (CAPR)

⚠️ No article content returned.

..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Unpacking a 167% Potential Upside

Taysha Gene Therapies, Inc. (NASDAQ: TSHA), a clinical-stage biotechnology company, has recently captured investor attention with a staggering potential upside of 167.27%. Specializing in the development..

Pharvaris N.V. (PHVS) Stock Analysis: Exploring a 103% Upside Potential in the Biotech Sector

Pharvaris N.V. (PHVS), a Swiss-based biotechnology company, has captured investor attention with its promising potential upside of 103.44%. As a late-stage biopharmaceutical company, Pharvaris is dedicated..

Simulations Plus, Inc. (SLP) Stock Analysis: A Compelling 44.86% Potential Upside in Health Information Services

Simulations Plus, Inc. (NASDAQ: SLP), a leading player in the health information services industry, offers a tantalizing opportunity for investors seeking exposure in the healthcare technology..

Altimmune, Inc. (ALT) Stock Analysis: Exploring a 266% Potential Upside with Strong Buy Ratings

Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company, has recently caught the attention of investors, particularly with its promising pipeline and a staggering potential upside of..

Nuvation Bio Inc. (NUVB) Stock Report: Exploring a 246.61% Potential Upside in the Innovative Oncology Space

For investors with a keen eye on the biotechnology sector, Nuvation Bio Inc. (NASDAQ: NUVB) presents a compelling opportunity. As a clinical-stage biopharmaceutical company, Nuvation Bio..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Unveiling a 429.95% Potential Upside

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is making waves in the biotechnology sector with a striking potential upside of 429.95%. This clinical-stage gene editing company, headquartered in..

REGENXBIO Inc. (RGNX): Analyst Ratings Highlight a 254% Potential Upside for This Biotech Innovator

REGENXBIO Inc. (NASDAQ: RGNX), a clinical-stage biotechnology company specializing in gene therapies, is capturing investor attention with a remarkable 253.96% potential upside, according to analyst ratings...

Zymeworks Inc. (ZYME): Analyst Ratings Suggest an 89.92% Upside Potential for Biotechnology Investors

For investors eyeing opportunities in the biotechnology sector, Zymeworks Inc. (NASDAQ: ZYME) presents a compelling case with its innovative approach to drug development and a notable..

Neuropace, Inc. (NPCE): Investor Outlook on a 29.67% Potential Upside in the Medical Devices Sector

Neuropace, Inc. (NPCE), a significant player in the healthcare sector, specifically within the medical devices industry, is drawing investor attention with its innovative approach to treating..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds